Drug-eluting implants for the suppression of metastatic bone disease: current insights. (3rd April 2018)

• Record Type: Journal Article
• Authors: Pountos, Ippokratis; Giannoudis, Peter V.
• Is Part Of: Expert review of medical devices. Volume 15:Number 4(2018)
• Page Start: 301
• Page End: 311
• Publication Date: 2018-04-03
• Subjects: Drug-eluting implants -- bone cement -- metastatic bone disease; Medical instruments and apparatus -- Periodicals; 610.28
• DOI: 10.1080/17434440.2018.1456336
• Languages: English
• ISSNs: 1743-4440

Abstract

ABSTRACT: Introduction : The fixation of impending or pathologic fractures is challenging and their successful management can have a favourable impact on the quality of life of the patient. The progression of the metastatic bone disease can cause significant pain and disability but also could result in the loosening and subsequent failure of the implants. To prevent the additional local growth, postoperative radiotherapy is often recommended, and many patients receive endocrine or chemotherapy Areas covered : Several reports support the antineoplastic drugs to bone cement as an adjuvant to improve implant stability as well as to prevent local cancer progression and failure of reconstructive devices used to treat patients with pathologic fractures. The aim of the present review is to present our current understanding on the effect of local delivery of antineoplastic drugs at the bone site. Expert commentary : Encouraging evidence support the application of bone cement loaded with antineoplastic drugs to fill defects and strengthen the fixation of orthopaedic implants. This is an inexpensive and safe method that can improve implant stability, prevent local cancer progression and failure of reconstructive devices. To fully evaluate its clinical effectiveness randomized clinical studies are needed.